Article Sidebar

Submitted
5 July 2018
Accepted
5 July 2018
Published
5 July 2018
Download
PDF
Statistic
Read Counter : 1587 Download : 1474

Main Article Content

Abstract

Nephrotic syndrome is a condition which is characterized by protein leakage from the blood to the urine through glomeruli. It leads to hypoproteinemia and generalised oedema. Patients with nephrotic syndrome need high dose and long term glucocorticoid such as prednisone. High dose and long term glucocorticoid can increase bone resorption. Biological marker is a valuable tool to evaluate efficacy of therapy. TRAP 5B is a sensitive biological marker for bone resorption because it reflects the number of osteoclasts. TRAP 5B is not affected by renal dysfunction and food. It also has a low diurnal variation than other bone resorption marker. The aim of this study was to analyze the changes of TRAP 5B levels at induction and alternate phase in children with steroid sensitive nephrotic syndrome. This observational prospective study was conducted from May to October 2016. Venous blood samples obtained at 08.00-10.00 am. TRAP5B levels were measured before and after induction phase and after alternate phase using ELISA. Fifteen patients were included in this study (60% boys). Majority of their age was 6 - <12 years and 40% were dependent steroid NS. TRAP 5B serum levels in induction phase increased by 37.41%±56.22%. In alternate phase, TRAP 5B serum levels increased by 28.75%±66.55% compared to the induction phase. However, the level change of both phases were not significant. As a conclusion, TRAP 5B levels increased in induction and alternate phase after high dose and long-term prednisone treatment in nephrotic syndrome.

Keywords

Nephrotic syndrome pediatric prednisone resorption TRAP 5B

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Setyani, D. S., Qibtiyah, M., Asmaningsih, N., & Yulistiani, Y. (2018). Analysis of High Dose and Long-Term Prednisone Therapy on Trap 5B Level Change in Children with Steroid Sensitive Nephrotic Syndrome. Folia Medica Indonesiana, 54(2), 116–122. https://doi.org/10.20473/fmi.v54i2.8861
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Canalis E, Mazziotti G, Giustina A, Bilezekian JP (2007). Glucocorticoid-induced osteoporosis: Patophysiology and therapy. Osteoporos Int 18, 1319-28
  2. Eknoyan G, Lameire N (2012). KDIGO clinical practice guideline for glomerulonephritis. Kidney Int, 143-274
  3. Hahn D, Hodson EM, Wilis NS, Craig JC (2015). Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev, CD005133
  4. Hansen KE, Kleker B, Safdar N, Bartels CM (2014). A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthri-tis Rheum 44, 47-54
  5. Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA (2007). Assessment of osteoclast number and function: Application in the development of new and improved treatment modalities for bone diseases. Osteoporosis Int 18, 681-85
  6. Jeon SH, Lim AY, Kim YK, Cheon HW, Yoo KH, Hong YS (1998). The effect of steroid therapy on growth and bone density in children with nephrotic syndrome. J Korean Pediatr Soc 41, 1396-1402
  7. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teltelbaum SL (2006). Glucocorticoids suppres bone formation via the osteoclast. J Clin Invest 116, 2152-2160
  8. Marie PJ (2010). The calcium-sensing receptor in bone cells: A potential therapeutic target in osteoporosis. Bone 46, 571-576
  9. Pais P, Avner ED (2015). Nephrotic syndrome. In: Kliegman RM, Stanton BF, St. Geme III JW, Schor NF. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, Elsevier, p 2521-28e1
  10. Raman V, Khrishnamurty S, Harichandrakumar KT (2015). Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: A randomized, open-label equivalence clinical trial. Pediatr Nephrol
  11. Sinha A, Menon S, Bagga A (2015). Nephrotic syndro-me: State of the art. Curr Pediatr Rep 3, 43-61
  12. Trihono PP, Alatas H, Tambunan T, Pardede SO (2012). Konsensus tata laksana sindrom nefrotik idiopatik pada anak edisi kedua. Jakarta, Badan Penerbit Ikatan Dokter Anak Indonesia
  13. Wheather G, Elsahaly M, Tuck SP, Datta HK, Laar JM (2013). The clinical utility of bone marker measure-ments in osteoporosis. J Transl Med 11, 201
  14. Zhang J, Zeng H, Fu S, Shi P, Wang M, Guo L (2016). Changes in dickkopf-1 and tartrate-resistant acid phosphatase 5B serum levels in preschool children with nephrotic syndrome. Biomed Rep 4, 605-08

Most read articles by the same author(s)

1 2 > >>